Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180739
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kahan, Zsuzsanna | - |
dc.contributor.author | Gil Gil, Miguel | - |
dc.contributor.author | Ruiz Borrego, Manuel | - |
dc.contributor.author | Carrasco, Eva | - |
dc.contributor.author | Ciruelos, Eva | - |
dc.contributor.author | Muñoz Mateu, Montserrat | - |
dc.contributor.author | Bermejo, Begoña | - |
dc.contributor.author | Margeli, Mireia | - |
dc.contributor.author | Antón, Antonio | - |
dc.contributor.author | Casas, Maribel | - |
dc.contributor.author | Csöszi, Tibor | - |
dc.contributor.author | Murillo, Laura | - |
dc.contributor.author | Morales, Serafín | - |
dc.contributor.author | Calvo, Lourdes | - |
dc.contributor.author | Lang, Istvan | - |
dc.contributor.author | Alba, Emilio | - |
dc.contributor.author | Haba Rodriguez, Juan de la | - |
dc.contributor.author | Ramos, Manuel | - |
dc.contributor.author | Álvarez López, Isabel | - |
dc.contributor.author | Gal Yam, Einav | - |
dc.contributor.author | García Palomo, Andrés | - |
dc.contributor.author | Alvarez, Elena | - |
dc.contributor.author | González Santiago, Santiago | - |
dc.contributor.author | Rodríguez, César A. | - |
dc.contributor.author | Servitja, Sonia | - |
dc.contributor.author | Corsaro, Massimo | - |
dc.contributor.author | Rodrigálvarez, Graciela | - |
dc.contributor.author | Zielinski, Christoph | - |
dc.contributor.author | Martín, Miguel | - |
dc.date.accessioned | 2021-10-21T12:58:03Z | - |
dc.date.available | 2021-10-21T12:58:03Z | - |
dc.date.issued | 2021-10-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/180739 | - |
dc.description.abstract | Background: The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was better tolerated. This analysis compared patient-reported outcomes. Patients and methods: The PEARL quality of life (QoL) population comprised 537 patients, 268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Patients completed the European Organisation for Research and Treatment of Cancer QLQC30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression models, respectively. Results: Questionnaire completion rate was high and similar between treatment arms. Significant differences were observed in the mean change in global health status (GHS)/QoL scores from the baseline to cycle 3 (2.9 for palbociclib/ET vs.-2.1 for capecitabine (95% confidence interval [CI], 1.4-8.6; P = 0.007). The median TTD in GHS/QoL was 8.3 months for palbociclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Similar improvements for palbociclib/ET were also seen for other scales as physical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differences were observed between the treatment arms in change from the baseline in any item of the EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale. Conclusion: Patients receiving palbociclib/ET experienced a significant delay in deterioration of GHS/QoL and several functional and symptom scales compared with capecitabine, providing additional evidence that palbociclib/ET is better tolerated. Trial registration number: NCT02028507 (ClinTrials.gov). EudraCT study number: 2013-003170-27. 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.ejca.2021.07.004 | - |
dc.relation.ispartof | European Journal of Cancer, 2021, vol. 156, p. 70-82 | - |
dc.relation.uri | https://doi.org/10.1016/j.ejca.2021.07.004 | - |
dc.rights | cc by-nc-nd (c) Kahan, Zsuzsanna et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Menopausa | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Menopause | - |
dc.subject.other | Clinical trials | - |
dc.title | Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-10-21T10:09:45Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34425406 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
This item is licensed under a
Creative Commons License